<DOC>
	<DOCNO>NCT00001992</DOCNO>
	<brief_summary>To test safety immunogenicity rgp 120/HIV-1IIIB vaccine HIV-1 seropositive adult patient .</brief_summary>
	<brief_title>A Phase I Study Safety Immunogenicity Rgp 120/HIV-1IIIB Vaccine HIV-1 Seropositive Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Stage 1 2 Walter Reed clinical stag HIV infected individual . The ability understand sign write informed consent form , must obtain prior study entry . Be available 24 week follow may complete . Qualify care Department Defense health care beneficiary . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Prior history clinically significant cardiac , pulmonary , hepatic , renal , neurologic autoimmune disease , HIV1 infection , less average general health determine medical history , physical examination , require laboratory test result . Concurrent Medication : Excluded : Corticosteroids know immunosuppressive drug . Any experimental agent . Patients follow exclude : Prior history clinically significant cardiac , pulmonary , hepatic , renal , neurologic autoimmune disease , HIV1 infection , less average general health determine medical history , physical examination , require laboratory test result . Prior Medication : Excluded within 30 day study entry : Zidovudine antiretroviral agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1992</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS Vaccines</keyword>
</DOC>